ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Oral hexavalent reassortant rotavirus attenuated live vaccine

Its studies are mostly in Gastroenteritis, led by Sinovac Biotech.

Furthest: phase 2, since Apr 26, 20252 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sinovac Biotech21 open or runningphase 2since Apr 26, 2025Apr 22, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 22, 2025First study: phase 1 study in Rotavirus GastroenteritisFirst studyNCT06950645 · 100 enrolled · China
  2. Apr 26, 2025Phase 2 study in Rotavirus GastroenteritisNCT06967272 · 400 planned · China

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Oral hexavalent reassortant rotavirus attenuated live vaccine”name, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06967272Rotavirus Gastroenteritis · China2RecruitingJun 15, 2026400
NCT06950645Rotavirus Gastroenteritis · China1CompletedDec 21, 2024100

How it is read

Names in the registry

  • “Oral hexavalent reassortant rotavirus attenuated live vaccine”, 6 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.